References: Hepatitis B and patients undergoing cancer chemotherapy or immunosuppression

  • Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology 2015;61(2):703–11. https://www.ncbi.nlm.nih.gov/pubmed/25412906
  • Doyle J, Raggatt M, Slavin M, McLachlan SA, Strasser SI, Sasadeusz JJ, et al. Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement. Med J Aust 2019;210(10):462–8. https://www.ncbi.nlm.nih.gov/pubmed/31104328
  • Hepatitis B Consensus Statement Working Group. Australian consensus recommendations for the management of hepatitis B infection. Melbourne: Gastroenterological Society of Australia; 2022. https://www.gesa.org.au/education/clinical-information/hbv-consensus-statement
  • Kusumoto S, Tanaka Y, Suzuki R, Watanabe T, Nakata M, Takasaki H, et al. Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study. Clin Infect Dis 2015;61(5):719–29. https://www.ncbi.nlm.nih.gov/pubmed/25935551
  • Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. J Gastroenterol Hepatol 2010;25(5):864–71. https://www.ncbi.nlm.nih.gov/pubmed/20546439